Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluating the effectiveness of Aspirin in Colorectal Cancer patients in terms of disease free survival and overall survival.

ABSTRACT: Interventions: An eligible subject will be randomised to the study in 1:1 ratio to either - Aspirin arm: 200 mg Aspirin once a day for 3 years - Placebo arm: 200 mg matching placebo once a day for 3 years. After randomisation, patient will have 3 monthly assessments for 3 years (month 3 to month 36) followed by 6 monthly assessments for additional 2 years (month 42 to month 60). Assessments include Haematology, Biochemistry, Colonoscopy, CT Scan, X-ray, ECG). Primary outcome(s): 1.Disease free survival (DFS) among all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer patient sub-groups) 2.DFS among patients with colon cancer (high-risk Dukes B and Dukes C colon cancer) [From randomization up to 5 years (3 monthly assessments for 3 years followed by 6 monthly assessments for additional 2 years)] Study Design: Randomized controlled trial

DISEASE(S): Colorectal Cancer

PROVIDER: 2564675 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

ASCOLT Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers.

Project description:Interventions: Eligible participants will be randomised to the study in 1:1 ration to either Aspirin arm: 200 mg Aspirin (oral tablet) once a day for 3 years or Placebo equivalent. The study treatment is given as adjuvant therapy Drug compliance will be monitored via drug dispensations and drug returns, recorded on drug accountability logs at each study visit. Noncompliance is defined as omission of more than 30% of the study period that the patient is on the study. Primary outcome(s): Disease Free Survival (DFS) among all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer patient sub-groups) [During treatment: prior to each treatment cycle. Patient will have 3 monthly assessments for 3 years (month 3 to month 36) followed by 6 monthly assessments for additional 2 years (month 42 to month 60).] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Safety/efficacy

| 2460879 | ecrin-mdr-crc

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Project description:We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally. STUDY OBJECTIVE To assess the effectiveness of Aspirin against placebo control in patients with dukes C or high risk dukes B colorectal cancer in terms of Disease Free Survival (DFS) and Overall Survival (OS) Primary endpoints * DFS among all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer patient sub-groups); * DFS among patients with colon cancer (high-risk Dukes B and Dukes C colon cancer). Secondary endpoints * Overall survival (OS) over 5 years * DFS and OS in * Chinese, Malay, Indian and other ethnic groups * Resected high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer sub-groups, individually * Compliant versus non-compliant subjects * PIK3CA mutated tumors (where samples are available)

| 2046934 | ecrin-mdr-crc

Phase III, Multi-centre, Double Blind, Randomized Placebo Controlled Trial of Aspirin for Duke C and High Risk Dukes B Colorectal Cancers

Project description:Intervention1: Aspirin: 200 mg OD for 3 years Control Intervention1: Placebo: 200 mg OD for 3 years Primary outcome(s): 1. Disease free survival for all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer ptient sub groups)Timepoint: 3 years;Disease free survival for colon cancer (high risk Dukes B and Dukes C colon cancer)Timepoint: 3 years Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant, Investigator and Outcome Assessor Blinded

| 2572425 | ecrin-mdr-crc

Transcription profiling of 10 sample types: normal colon tissue, non cancerous adenomas, Dukes B carcinomas, Dukes C carcinomas, Dukes D carcinomas, and liver metastases, see also E-TIGR-14, E-TIGR-15

Project description:This study was designed to find patterns of gene expression in colon cancer samples that correlate with clinical stage. Ten samples were profiled from each of the following sample types: normal colon tissue, noncancerous adenomas, Dukes B carcinomas, Dukes C carcinomas, Dukes D carcinomas, and liver metastases. See also E-TIGR-14, E-TIGR-15

2005-01-01 | E-TIGR-14 | biostudies-arrayexpress

Transcription profiling of ten human samples of normal colon tissue, noncancerous adenomas, Dukes B carcinomas, Dukes C carcinomas, Dukes D carcinomas, and liver metastases

2005-01-01 | E-TIGR-15 | biostudies-arrayexpress

Transcription profiling of ten human samples of normal colon tissue, noncancerous adenomas, Dukes B carcinomas, Dukes C carcinomas, Dukes D carcinomas, and liver metastases

2005-01-01 | E-TIGR-16 | biostudies-arrayexpress

Transcriptome-wide in vitro effects of aspirin on patient-derived normal colon organoids

Project description:Here, we used bulk RNA-seq data derived from healthy colon organoids (un)exposed to aspirin. Through the use of external single cell RNA-seq data, we estimate changes in cell composition. We extend this analysis by controlling for cell composition and performing WGCNA to identify modules of co-expression differentially affected by aspirin treatment in colon organoids.

2021-01-31 | GSE163282 | GEO

Associations between pre-diagnostic aspirin use and ovarian tumor gene expression

Project description:Aspirin use has been associated with reduced ovarian cancer risk. However, the underlying biological mechanisms are not fully understood We examined the association between gene expression profiles in ovarian tumors and current low and regular dose aspirin use in the 1-2 years prior to diagnosis

2023-10-03 | GSE230522 | GEO